Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.87 |
| ▸ | MAPT | P10636 | 3/20 | 0.87 |
| ▸ | CTSB | P07858 | 2/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603799 | 1.00 | APP (0.87) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL1607405 | 0.93 | APP (1.00) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL13191839 | 0.93 | APP (1.00) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL10167885 | 0.93 | APP (1.00) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL29373798 | 0.93 | APP (1.00) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL17675281 | 0.89 | APP (0.70) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL17675282 | 0.89 | APP (0.70) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL1976945 | 0.88 | CYP1A2 (0.81) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL19872782 | 0.87 | APP (0.82) | APPMAPTCTSBCAPN1CYP1A1 | |
| SCHEMBL16674442 | 0.87 | APP (0.88) | APPMAPTCTSBCAPN1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242144-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | RESVERLOGIX CORP. | 2011-04-07 | — | — | US | disclosed |
| US-7846915-B2 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
| WO-2006045010-A2 | STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205792-A1 | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases | APOB, APOL1, HDLBP | APP 571/4885MAPT 2177/4885CTSB 1264/4885 |
| US-20110082176-A1 | Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases | APOB, APOL1, HDLBP | APP 571/4885MAPT 2177/4885CTSB 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.